<DOC>
	<DOCNO>NCT01494259</DOCNO>
	<brief_summary>This double-blind , randomize , control clinical trial compare patient-reported pain pain medication/narcotic use patient randomize treatment ( bupivacaine ) placebo ( saline ) deliver via pain pump mastectomy site . Candidates chosen mastectomy one side immediately follow tissue expander placement breast reconstruction . Patients randomize 1:1 bupivacaine- ( treatment ) saline- ( placebo ) fill percutaneously-placed pain pump ; neither participant study staff know participant ' treatment . Data patient-perceived pain pain medication use collect surgery , surgery , surgery Days 1 , 2 , 3 , 7 , 90 , Years 2 4 phone . The investigator hypothesize patient randomize treatment ( bupivacaine ) group significantly low pain score use less pain medicine patient receive placebo first 90 day follow surgery . The Year 2 Year 4 follow-up include tertiary endpoint capture differences chronic pain , patient ask complete questionnaire Day 90 follow .</brief_summary>
	<brief_title>Bupivacaine Pain Pumps Decrease Mastectomy Post-Operative Pain</brief_title>
	<detailed_description>Double-blind , randomize , control clinical trial compare patient-reported pain pain medication/narcotic use patient randomize treatment ( bupivacaine ) placebo ( saline ) deliver via pain pump mastectomy site . Candidates elect undergo unilateral post-mastectomy immediate tissue expander breast reconstruction . Participants meet inclusion criterion enrol baseline data collection complete prior randomization surgery . Patients randomize 1:1 bupivacaine- ( treatment ) saline- ( placebo ) fill percutaneously-placed pain pump double-blinded design . Patient-specific surgical detail record intraoperatively . Following surgery , post-operative pain , pain medication/narcotic use , assessment adverse event ( AEs ) /serious adverse event ( SAEs ) assess Days 1 , 2 , 3 . A clinic visit occur Day 7 pain pump remove additional data collect ( updated medical history , pain medication/narcotic use , AEs/SAEs , study questionnaire ) . A Pain Pump Questionnaire complete obtain patient 's assessment usability pain pump . Long-term quality-of-life/health outcome assessments do post-operative Day 90 ( ±14 day ) , Year 2 ( ±14 day ) , Year 4 ( ±14 day ) . The Year 2 Year 4 follow-up include tertiary endpoint capture differences chronic pain , patient ask complete questionnaire Day 90 follow .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Be Female age 18100 year . Choose unilateral mastectomy follow immediate tissue expander breast reconstruction . Have inflammatory breast cancer . Be aware nature malignancy . Understand study purpose , requirement , risk . Be able willing give inform consent . Any concurrent narcotic analgesic use ( baseline narcotic use must 0 eligible ) . Axillary lymph node dissection relate qualify mastectomy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>immediate breast reconstruction</keyword>
	<keyword>pain control</keyword>
	<keyword>post mastectomy pain control</keyword>
</DOC>